Raunak Parikh, O'Mareen Spence, Nikolaos Giannelos, Iain Kaan
INTRODUCTION: Herpes zoster (HZ; shingles) is a painful, cutaneous disease caused by reactivation of the varicella zoster virus, which causes varicella (chickenpox) typically during childhood. The considerable healthcare burden of HZ is relatively well documented, with approximately one in three individuals experiencing at least one episode during their lifetime, debilitating symptoms including neuropathic pain, and complications such as post-herpetic neuralgia, vision loss, and rarely, stroke, and increased severity in immunocompromised individuals...
February 28, 2024: Dermatology and Therapy
Efstratios Vakirlis, Stamatios Gregoriou, Katerina Bakirtzi, Eleni Paschou, Aikaterini Tsiogka, Ilias Papadimitriou, Eleni Sotiriou
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized clinically by pruritus, and pathophysiologically by immune dysregulation, and compromised skin barrier function. While topical therapies are currently the cornerstone of AD management, especially in mild disease, recent advancements in systemic treatments and a deeper understanding of similar skin diseases, such as psoriasis, have highlighted the importance of early intervention. In this commentary, we explore the potential benefits of early systemic intervention in AD, with pruritus determining such a decision...
February 27, 2024: Dermatology and Therapy
Tomasz Skrzypczak, Anna Skrzypczak, Jacek C Szepietowski
INTRODUCTION: Patients search on the Internet for information about various medical procedures and conditions. The main aim of this study was to evaluate the readability of online health information related to atopic dermatitis (AD). Online resources are becoming a standard in facilitating shared decision-making processes. With a pipeline of new therapeutic options like immunomodulators, understanding of the complexity of AD by the patients is crucial. METHODS: The term "atopic dermatitis" translated into 23 official European Union languages was searched using the Google search engine...
February 24, 2024: Dermatology and Therapy
Valerie J Ludbrook, David C Budd, Katie Thorn, Debra Tompson, Bartholomew J Votta, Lucy Walker, Amy Lee, Xin Chen, Amanda Peppercorn, Wei Jing Loo
INTRODUCTION: Receptor-interacting protein kinase 1 (RIPK1), a key mediator of inflammation through necroptosis and proinflammatory cytokine production, may play a role in the pathogenesis of immune-mediated inflammatory diseases such as chronic plaque psoriasis. An experimental medicine study of RIPK1 inhibition with GSK2982772 immediate-release formulation at doses up to 60 mg three times daily in mild to moderate plaque psoriasis indicated that efficacy may be improved with higher trough concentrations of GSK2982772...
February 19, 2024: Dermatology and Therapy
Mike Bastian, Nick Freemantle, Ana B Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
No abstract text is available yet for this article.
February 16, 2024: Dermatology and Therapy
Tina Bhutani, Aaron S Farberg
Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening disease. There is limited understanding of patient characteristics in GPP and their correlation with disease progression or healthcare resource utilization. Our review aims to examine real-world evidence on these characteristics and the associated disease burden as related to economic and quality of life factors. Results showed that most patients with GPP experienced flares once a year, lasting from 2 weeks to 3 months, with > 80% of patients having residual disease post-flare, with/without treatment, indicating the long-term nature of GPP...
February 16, 2024: Dermatology and Therapy
Sascha Gerdes, Anna Campanati, Gudrun Ratzinger, Bruno Halioua, Martin Krogager Eeg, Georgios Pesiridis, Marie Y Jablonski Bernasconi, Elizabeth Lazaridou
INTRODUCTION: Plaque psoriasis is a chronic relapsing inflammatory skin disease that is associated with extensive disease burden that often requires long-term therapy. Treatment of psoriasis with 4 weeks of the aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD; Enstilar®, LEO Pharma) has been demonstrated to be effective, well tolerated, and associated with high patient satisfaction. Cal/BD foam is approved as a first-line treatment in multiple countries, where several non-interventional studies (NIS) have corroborated the beneficial efficacy and safety profiles determined in the randomized clinical trials...
February 15, 2024: Dermatology and Therapy
Paweł Pietkiewicz, Cristian Navarrete-Dechent, Yaei Togawa, Piotr Szlązak, Natalia Salwowska, Ashfaq A Marghoob, Agnieszka Leszczyńska-Pietkiewicz, Enzo Errichetti
Dermatoscopy is a non-invasive and cost-efficient imaging technique augmenting clinical examination in neoplastic and non-neoplastic dermatoses. Recently, novel dermatoscopic techniques based on principles of reflectance/absorption and excited fluorescence have been developed. However, comprehensive data on their applications are sparse, and terminology is inconsistent. In this systematic review, we addressed the principles of ultraviolet (UV) imaging and proposed categorization based on spectral characteristics and signal acquisition, as well as discussed documented and potential clinical applications, safety measures during examination, and limitations associated with reflectance and fluorescence dermatoscopy...
February 15, 2024: Dermatology and Therapy
Andreas Pinter, Athanasios Tsianakas, Adina Eichner
INTRODUCTION: Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is approved as an ointment formulation for the treatment of atopic dermatitis. The efficacy and safety of topically applied tacrolimus have also been studied and proven for psoriasis. However, no proprietary pharmaceutical product is currently approved for this indication...
February 12, 2024: Dermatology and Therapy
Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F Merola, Ken Gordon, Mona Shahriari, Neil J Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
INTRODUCTION: Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab...
February 10, 2024: Dermatology and Therapy
Gastón Roustán, Marta Loro, Ángel Rosell, Belén Menchen, Olga Vicente, Marta Elosua-González, Juan L Castaño, Catalina Peña, Olga Isidoro
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin condition that affects both children and adults. AD increases the risk of developing comorbidities like asthma, allergic rhinitis and food allergies. AD patients face difficulties, including itching, lack of effective treatments, lack of funding and discomfort in seeking a diagnosis or treatment. This study aims to identify the main barriers and opportunities to improve the experience of patients with AD and provide high-quality care...
February 9, 2024: Dermatology and Therapy
Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green
INTRODUCTION: When assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for ixekizumab (IXE), an interleukin-17A antagonist, and guselkumab (GUS), an interleukin-23p19 inhibitor, in different body regions of patients with moderate-to-severe plaque PsO participating in the IXORA-R study, up to week 24...
February 9, 2024: Dermatology and Therapy
Hidehisa Saeki, Yoko Kataoka, Takafumi Etoh, Norito Katoh, Satoshi Teramukai, Yuki Tajima, Hiroyuki Fujita, Marius Ardeleanu, Kazuhiko Arima
INTRODUCTION: Atopic dermatitis (AD) is a chronic relapsing condition with high disease burden and impact on health-related quality of life (HRQoL). Correlations between clinician- and patient-reported outcomes tend to be poor, and limited data in Asian patients are available. METHODS: ADDRESS-J was a prospective, non-interventional, longitudinal study that evaluated the real-world effectiveness and safety of AD treatment in Japanese adults (aged 20-59 years) with moderate-to-severe AD...
February 7, 2024: Dermatology and Therapy
Leonor Girão, Pedro Pinto
INTRODUCTION: Striae distensae (SD), or stretch marks, are a common skin problem having a psychological impact and cosmetic concern, especially for women, in whom the prevalence is higher than in men. This study assessed the efficacy and safety of a single autologous micrografting treatment (AMT® ) using Rigenera® technology for the management of SD. METHODS: This single-centre study included 10 healthy women between 24 and 65 years of age, with Fitzpatrick-Goldman skin types I-IV, who had visible SD in glutes/thighs...
February 6, 2024: Dermatology and Therapy
Lakshi M Aldredge, Winston D Chamberlain, Vivian Y Shi
There is a growing awareness among dermatology providers of ocular comorbidities in patients with the chronic inflammatory skin disease atopic dermatitis (AD). For example, the prevalence of ocular surface diseases (OSD) such as conjunctivitis is higher in patients with AD than in the general population, and the use of some AD treatments may be associated with OSD. In a recent review published in the Journal of the American Academy of Dermatology, dermatologists and ophthalmologists provided an overview of the different types, etiology, pathophysiology, and practical management of OSD associated with AD...
February 3, 2024: Dermatology and Therapy
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M Schempp, Kim Petersen, Mia M Noergaard, Lluis Puig
INTRODUCTION: Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. METHODS: COBRA (NCT04533737) was a randomized (1:1), blinded (patient and assessor), 28-week, active-comparator trial conducted in Europe from December 2020 to December 2022. The objective was to compare the efficacy and safety of brodalumab versus guselkumab in adults with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab...
February 1, 2024: Dermatology and Therapy
Hannah Kaiser, Charlotte Näslund-Koch, Amanda Kvist-Hansen, Lone Skov
Psoriasis is an immune-mediated inflammatory disease associated with an increased risk of cardiovascular disease (CVD). The risk of CVD increases with the severity of psoriasis, and exposure to systemic inflammation may partly explain the increased risk of CVD in these patients. This raises the question of whether anti-psoriatic treatment, in addition to treating the skin lesions, also lowers the risk of developing CVD. Different types of studies have examined the impact of systemic anti-psoriatic treatments on the risk of CVD in patients with psoriasis and epidemiological observational studies with, e...
January 30, 2024: Dermatology and Therapy
Panittra Suphatsathienkul, Kullasate Sakpichaisakul, Thanin Wechapinan, Objoon Trachoo, Sorawit Virawan, Rungsima Wanitphakdeedecha
Schwartz-Jampel syndrome (SJS) is a rare autosomal recessive disorder characterized by typical facial dysmorphism, generalized muscle stiffness, joint contracture, and skeletal abnormalities. This condition is caused by mutations in the heparan sulfate proteoglycan 2 (HSPG2) gene, which encodes perlecan, a component of the basement membrane. The management of patients with SJS primarily aims to alleviate symptoms related to muscle stiffness. In this report, we describe a male patient with SJS type 1A...
January 28, 2024: Dermatology and Therapy
April W Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Dipen Patel, Lauren Seigel
INTRODUCTION: While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily oral psoriasis treatment, elicit patient views on treatment characteristics, and rank treatment characteristics by importance. METHODS: This noninterventional, cross-sectional survey study, conducted from December 2021 to June 2022, recruited US adults with moderate to severe psoriasis...
January 22, 2024: Dermatology and Therapy
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José-Carlos Armario-Hita
No abstract text is available yet for this article.
January 20, 2024: Dermatology and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.